Figure 5.
Figure 5. Cleavage of Bcl-xL is required for the uptake of L88 exosomes by MM and ALCL cells. (A) Percentage of RPMI 8226 PKH67-positive cells after 3 hours of incubation with L88, L88 Bcl-xL, or Bcl-xL D/A PKH67-labeled exosomes, pretreated with the caspase inhibitors zVAD.fmk or DEVD.fmk (mean ± SD, n = 3). *P < .05, **P < .01, ***P < .001. DMSO, dimethyl sulfoxide; -ve, negative. (B) Percentage of OPM2 PKH67-positive cells after 3 hours of incubation with L88, L88 Bcl-xL, or Bcl-xL D/A PKH67-labeled exosomes, pretreated with the caspase inhibitors zVAD.fmk or DEVD.fmk (mean ± SD, n = 3). *P < .05, **P < .01, ***P < .001. (C) Percentage of SupM2 or Mac2a PKH67-positive cells after 3 hours of incubation with L88, L88 Bcl-xL, or Bcl-xL D/A PKH67-labeled exosomes (mean ± SD, n = 3) *P < .05, **P < .01.

Cleavage of Bcl-xL is required for the uptake of L88 exosomes by MM and ALCL cells. (A) Percentage of RPMI 8226 PKH67-positive cells after 3 hours of incubation with L88, L88 Bcl-xL, or Bcl-xL D/A PKH67-labeled exosomes, pretreated with the caspase inhibitors zVAD.fmk or DEVD.fmk (mean ± SD, n = 3). *P < .05, **P < .01, ***P < .001. DMSO, dimethyl sulfoxide; -ve, negative. (B) Percentage of OPM2 PKH67-positive cells after 3 hours of incubation with L88, L88 Bcl-xL, or Bcl-xL D/A PKH67-labeled exosomes, pretreated with the caspase inhibitors zVAD.fmk or DEVD.fmk (mean ± SD, n = 3). *P < .05, **P < .01, ***P < .001. (C) Percentage of SupM2 or Mac2a PKH67-positive cells after 3 hours of incubation with L88, L88 Bcl-xL, or Bcl-xL D/A PKH67-labeled exosomes (mean ± SD, n = 3) *P < .05, **P < .01.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal